Novel therapeutic processes for establishing or enhancing an immunized state, and compositions useful therefor

a technology of immunization state and composition, applied in the field of therapeutic process and therapeutic composition, can solve the problems of unidirectional attempts at altering a pre-existing immune state, drawback of dual therapeutic or pathogen management procedures, and the consideration of benefits outweighed the benefits, so as to achieve the effect of at least decreasing

Inactive Publication Date: 2005-06-02
ENZO THERAPEUTICS ENZO BIOCHEM
View PDF25 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although proteins expressed by these cells are derived from the genetic information of the subject, recognition as antigens may still take place when they are mutated or inappropriately-expressed in a subject.
In prior art, attempts at alteration of a pre-existing immune state are still of a unidirectional nature.
However, the drawback of a need for such dual therapeutic or pathogen management procedures was considered to be outweighed by benefits that would be provided by the reduction of immune responses that contribute to aspects of the disease state.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

[0057] Fifteen subjects were enrolled in the clinical study. The subjects were men or women with a diagnosis of active HBV infection (acute or chronic) based on liver biopsy (active inflammatory response), and positive for HBsAg with liver enzymes at least twice above normal. The subjects were required to meet one or more of the following criteria: (1) failed treatment with interferon or were unable to receive interferon; (2) hepatocellular carcinoma and active inflammatory response; (3) fulminant liver failure or severe deteriorating synthetic liver functions; (4) liver transplant recipient with evidence of reinfection of the graft and active inflammatory reaction in the liver, who failed or were unable to receive interferon or lamivudine; and (5) had HBV immune mediated disease (i.e., cryo, PAN, neuropathy, kidney involvement).

[0058] The subjects were fed with recombinant HbsAg preS1+preS2 twice a day for 20 weeks. The HBV antigen was given in liquid form, ...

example 2

Materials & Methods:

[0078] Mice: Female immunocompetent (heterozygous) and athymic Balb / c mice were purchased from Jackson Laboratories, Bar Harbor, Me. All animals were kept in laminar flow hoods in sterilized cages, receiving irradiated food and sterile acidified water as described (Shouval et al., “Comparative morphology and tumorigenicity of human hepatocellular cell carcinoma lines in athymic rats and mice;”Vichow's Archives A. Path. His. 412:595-606, (1988)).

[0079] Cell cultures: The human hepatoma cell line Hep-3B which secretes HBsAg was grown in culture as a monolayer, in medium supplemented with non essential amino acids and 10% heat inactivated fetal bovine serum as described (American Type Culture Collection, ATCC, HB-8064, HB-8065; Shouval et al., Vichow's Archives A. Path. His., supra;).

[0080] Induction of anti-HBV immune response: BioHepB recombinant hepatitis B vaccine (BioTechnology General LTD, Israel) which contains three surface antigens of the hepatitis B vi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
resistanceaaaaaaaaaa
reactivityaaaaaaaaaa
immune reactivityaaaaaaaaaa
Login to view more

Abstract

This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination processes for preventing infections in subjects are also provided. The novel processes comprise introducing into or adminstering to a subject one or more antigens, or trained or adopted immune cells. These antigens or immune cells are capable of establishing or increasing at least one first specific immune response and decreasing at least one second specific immune response. Such responses include components, such as cellular immune reaction elements, humoral immune reaction elements and cytokines, the latter also encompassing interferons and lymphokines. Useful compositions are also provided by this invention.

Description

FIELD OF THE INVENTION [0001] This invention relates to the field of therapeutic processes and therapeutic compositions, including treatments and compositions directed against infectious agents, cancerous conditions and immunity disorders. This invention also relates to therapeutic processes and compositions in vaccination and immunization. [0002] All patents, patent applications, patent publications, scientific articles and the like, cited or identified in this application are hereby incorporated by reference in their entirety in order to describe more fully the state of the art to which the present invention pertains. BACKGROUND OF THE INVENTION [0003] Antigenic stimulation of the immune system induces a series of reactions which can be mediated by immunological components such as the humoral, cellular or cytokine responses. The directionality of these reactions can be considered to be of a reactive or suppressive nature. For instance, in the context of the present invention, an i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/12A61K38/095A61K39/00A61K39/21A61K39/29A61P31/00A61P31/12A61P31/18A61P35/00A61P37/02A61P37/04
CPCA61K39/0005A61K39/001A61K39/292A61K2035/122C12N2730/10134A61K2039/542A61K2039/57A61K38/00A61K2039/5152A61K39/12A61P31/00A61P31/12A61P31/18A61P31/20A61P31/22A61P35/00A61P37/02A61P37/04
Inventor ILAN, YARONRABBANI, ELAZARENGELHARDT, DEAN L.GOTSMAN, ISRAELDONEGAN, JAMES J.
Owner ENZO THERAPEUTICS ENZO BIOCHEM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap